Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

49,672 (281,800) 206,587 (133,273)

INCOME TAX EXPENSE (BENEFIT) (62,371) 24,963 (4,375) 102,613

NET INCOME (LOSS) $112,043 $(306,763) $210,962 $(235,886)

BASIC INCOME (LOSS) PER

COMMON SHARE $1.64 $(4.58) $3.11 $(3.55)

DILUTED INCOME (LOSS) PER

COMMON SHARE $1.42 $(4.58) $2.79 $(3.55)

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 68,118 66,931 67,855 66,398

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,920 66,931 75,580 66,398

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Three Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $112,043 $(306,763)

Cost of sales adjustments 54,569 (1) 22,255 (1)

Research and development adjustments 259 (2) 15,000 (2)

Selling, general and administrative

adjustments 27,169 (3) -

Settlement reserve 7,450 (4) 369,000 (4)

Gain on extinguishment of debt - (5,319) (5)

Interest expense adjustment 3,750 (6)

Restructuring charges 1,497 (7)

Income tax adjustment (113,832) (8) (21,693) (8)

(19,138) 379,243

ADJUSTED NET INCOME $92,905 $72,480

BASIC ADJUSTED INCOME PER COMMON

SHARE $1.36
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Industry ... Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business operations ... iLab’s suite of tools. This entails not only introducing iLab to potential partners ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain ... management and resiliency practitioners with luminaries and thought leaders to advance the professional ... for their innovations and performance excellence. At that time its principle sponsor, ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.20 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... MARLBOROUGH, Mass. , Aug. 31, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that the 30-day review period ... Drug (IND) for ocular indications with the U.S. ... the IND is now active. ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... Cardium Therapeutics,(Amex: CXM ) announced that it ... investor that participated in its prior financing for,the ... warrants to purchase,additional shares of common stock. The ... $3.25 million, before placement agent,fees and offering expenses ...
... SemBioSys subsidiary to accelerate commercialization,of personal care ingredients with its proprietary oleosome-based technology ... ... ... Botaneco Specialty,Ingredients Inc. (,Botaneco,), a wholly-owned subsidiary of SemBioSys,Genetics Inc. (,SemBioSys,), today announced that ...
... VEDBAEK, Denmark, June 30 Exiqon A/S today,received information ... Danica Pension Livsforsikring and Danske Fund FCP - through,acquisition ... a nominal,value of each DKK 1 corresponding to 5,99% ... in Exiqon A/S., About Exiqon, Exiqon,s corporate ...
Cached Biology Technology:Cardium Announces Follow-On Direct Investment by Institutional Investor 2Cardium Announces Follow-On Direct Investment by Institutional Investor 3Cardium Announces Follow-On Direct Investment by Institutional Investor 4Botaneco announces $4,000,000 financing 2Botaneco announces $4,000,000 financing 3Botaneco announces $4,000,000 financing 4
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... first time, ultrasound is being used in animal models ?to ... University of Pennsylvania School of Medicine completed a study in ... tumor's blood perfusion and then to treat it with a ... at an intensity similar to what is used in physiotherapy ...
... Yale have brought to light a mechanism that regulates ... as cells prepare to divide, according to a report ... of cell biology , and his colleagues at ... Sickness. Like many parasites, it is exceptionally streamlined and ...
... Really old, in fact, which comes as a surprise to ... in the world's largest tropical region. , Using radiocarbon dating ... that up to half of all trees greater than 10 ... of the trees, Trumbore said, are as much as 750 ...
Cached Biology News:Penn researchers study the use of ultrasound for treatment of cancer 2Sleeping sickness parasite shows how cells divide their insides 2Amazon trees much older than assumed, raising questions on global climate impact of region 2
...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Jak3 Antibody Ship: Hot Store: -20 C...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: